Literature DB >> 30214544

Regulation of mPGES-1 composition and cell growth via the MAPK signaling pathway in jurkat cells.

Yi-Qing Li1,2, Jiao-Ting Chen1,2,3, Song-Mei Yin1, Da-Nian Nie1, Zhi-Yuan He1, Shuang-Feng Xie1, Xiu-Ju Wang1, Yu-Dan Wu1, Jie Xiao1, Hong-Yun Liu1, Jie-Yu Wang1, Wen-Juan Yang1, Li-Ping Ma1.   

Abstract

Previous studies have suggested that microsomal prostaglandin E synthase-1 (mPGES-1) is highly expressed and closely associated with mitogen-activated protein kinase (MAPK) signaling pathways in various types of malignant cells. However, their expression patterns and function with respect to T-cell acute lymphoblastic leukemia (T-ALL) remain largely unknown. The present study investigated whether mPGES-1 served a crucial role in T-ALL and aimed to identify interactions between mPGES-1 and the MAPK signaling pathway in T-ALL. The results indicated that mPGES-1 overexpression in T-ALL jurkat cells was significantly decreased by RNA silencing. Decreasing mPGES-1 on a consistent basis may inhibit cell proliferation, induce apoptosis and arrest the cell cycle in T-ALL jurkat cells. Microarray and western blot analyses revealed that c-Jun N-terminal kinase served a role in the mPGES-1/prostaglandin E2/EP4/MAPK positive feedback loops. In addition, P38 and extracellular signal-regulated kinase 1/2 exhibited negative feedback effects on mPGES-1. In conclusion, the results suggested that cross-talk between mPGES-1 and the MAPK signaling pathway was very complex. Therefore, the combined regulation of mPGES-1 and the MAPK signaling pathway may be developed into a new candidate therapy for T-ALL in the future.

Entities:  

Keywords:  T-cell acute lymphoblastic leukemia; feedback; jurkat cell; microsomal prostaglandin-E synthase; mitogen activated protein Kinase Signaling System

Year:  2018        PMID: 30214544      PMCID: PMC6125822          DOI: 10.3892/etm.2018.6538

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  45 in total

Review 1.  Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways.

Authors:  W-L Zhao
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528

2.  Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Authors:  Huizhong Hu; Alexey Goltsov; James L Bown; Andrew H Sims; Simon P Langdon; David J Harrison; Dana Faratian
Journal:  Cell Signal       Date:  2012-09-18       Impact factor: 4.315

3.  Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells.

Authors:  Yuseok Moon; Myoungjoo Lee; Hyun Yang
Journal:  Biochem Pharmacol       Date:  2006-08-26       Impact factor: 5.858

4.  Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways.

Authors:  Dalila Naci; Fawzi Aoudjit
Journal:  Cell Signal       Date:  2014-05-29       Impact factor: 4.315

5.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

Review 6.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

7.  COX2 and PGE2 mediate EGF-induced E-cadherin-independent human ovarian cancer cell invasion.

Authors:  Xin Qiu; Jung-Chien Cheng; Hsun-Ming Chang; Peter C K Leung
Journal:  Endocr Relat Cancer       Date:  2014-08       Impact factor: 5.678

Review 8.  COX-2 inhibitors for the prevention of breast cancer.

Authors:  Louise R Howe; Andrew J Dannenberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

9.  mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.

Authors:  Federica Finetti; Erika Terzuoli; Antonio Giachetti; Raffaella Santi; Donata Villari; Hiromi Hanaka; Olof Radmark; Marina Ziche; Sandra Donnini
Journal:  Endocr Relat Cancer       Date:  2015-06-25       Impact factor: 5.678

10.  Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis.

Authors:  Ki Mo Kim; A-Rang Im; Seung Hyung Kim; Jin Won Hyun; Sungwook Chae
Journal:  Cancer Sci       Date:  2016-01-22       Impact factor: 6.716

View more
  3 in total

1.  Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1.

Authors:  Krista LaBorde; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2022-01-05       Impact factor: 3.808

2.  mPGES-1/PGE2 promotes the growth of T-ALL cells in vitro and in vivo by regulating the expression of MTDH via the EP3/cAMP/PKA/CREB pathway.

Authors:  Yiqing Li; Jiaoting Chen; Wenjuan Yang; Hongyun Liu; Jieyu Wang; Jie Xiao; Shuangfeng Xie; Liping Ma; Danian Nie
Journal:  Cell Death Dis       Date:  2020-04-06       Impact factor: 8.469

3.  Growth of T-cell lymphoma cells is inhibited by mPGES-1/PGE2 suppression via JAK/STAT, TGF-β/Smad3 and PI3K/AKT signal pathways.

Authors:  Yiqing Li; Meng Qiu; Boqi Li; Jie Xiao; Wenjuan Yang; Shuangfeng Xie; Yumo Du; Kezhi Huang; Danian Nie
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.